{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:52:49Z","timestamp":1788839569209,"version":"build-2803163510"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.juro.2006.06.047","type":"journal-article","created":{"date-parts":[[2006,9,4]],"date-time":"2006-09-04T11:12:26Z","timestamp":1157368346000},"page":"1344-1348","source":"Crossref","is-referenced-by-count":32,"title":["Phase I\/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer"],"prefix":"10.1097","volume":"176","author":[{"given":"Rajiv","family":"Puri","sequence":"first","affiliation":[{"name":"Department of Urology, Bradford Royal Infirmary, Bradford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Palit","sequence":"additional","affiliation":[{"name":"Department of Urology, Bradford Royal Infirmary, Bradford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Loadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Flannigan","sequence":"additional","affiliation":[{"name":"Department of Urology, Bradford Royal Infirmary, Bradford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Urology, Bradford Royal Infirmary, Bradford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guzanfar A.","family":"Choudry","sequence":"additional","affiliation":[{"name":"Department of Urology, Bradford Royal Infirmary, Bradford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurajyoti","family":"Basu","sequence":"additional","affiliation":[{"name":"Department of Urology, Bradford Royal Infirmary, Bradford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Double","sequence":"additional","affiliation":[{"name":"Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Lenaz","sequence":"additional","affiliation":[{"name":"Spectrum Pharmaceuticals, Inc., Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanta","family":"Chawla","sequence":"additional","affiliation":[{"name":"Spectrum Pharmaceuticals, Inc., Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Beer","sequence":"additional","affiliation":[{"name":"Spectrum Pharmaceuticals, Inc., Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coen","family":"Van Kalken","sequence":"additional","affiliation":[{"name":"NDDO Oncology B. V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"de Boer","sequence":"additional","affiliation":[{"name":"NDDO Oncology B. V., Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[{"name":"Slotervaart Hospital, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Twelves","sequence":"additional","affiliation":[{"name":"Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Phillips","sequence":"additional","affiliation":[{"name":"Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2006.06.047_bib1","first-page":"461","article-title":"Enzyme directed bioreductive drug development revisited","volume":"6","author":"Workman","year":"1994","journal-title":"Oncol Res"},{"key":"10.1016\/j.juro.2006.06.047_bib2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/0959-8049(94)90134-1","article-title":"Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro","volume":"30A","author":"Robertson","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.juro.2006.06.047_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/jnci\/88.5.259","article-title":"Reductase enzyme expression across the National Cancer Institute tumour cell line panel","volume":"88","author":"Fitzsimmons","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2006.06.047_bib4","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/bjc.1994.461","article-title":"DT-diaphorase protects cells from the hypoxic cytotoxicity of indolequinone EO9","volume":"70","author":"Plumb","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2006.06.047_bib5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0959-8049(05)80434-4","article-title":"EO9","volume":"29A","author":"Hendriks","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.juro.2006.06.047_bib6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/jnci\/86.12.906","article-title":"Phase I and pharmacological study of the novel indolequinone bioreductive alkylating cytotoxic drug EO9","volume":"86","author":"Schellens","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2006.06.047_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/oxfordjournals.annonc.a010645","article-title":"A randomized phase II study with two schedules of the novel indolequinone EO9 in non-small-cell lung cancer","volume":"7","author":"Pavlidis","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.juro.2006.06.047_bib8","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/0959-8049(96)00226-2","article-title":"EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group","volume":"32A","author":"Dirix","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.juro.2006.06.047_bib9","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/bjc.1998.355","article-title":"Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours","volume":"77","author":"Phillips","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2006.06.047_bib10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/sj.bjp.0704916","article-title":"Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9","volume":"137","author":"Loadman","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.juro.2006.06.047_bib11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1054\/bjoc.2001.2056","article-title":"A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9","volume":"85","author":"Choudry","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2006.06.047_bib12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6601260","article-title":"GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer","volume":"89","author":"Hoskin","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2006.06.047_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1078-1439(01)00156-9","article-title":"The use of the marker tumour concept in Ta, T1 bladder cancer","volume":"7","author":"Van der Meijden","year":"2002","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2006.06.047_bib14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/bjc.1992.73","article-title":"In vitro activity of the novel indolequinone EO9 and the influence of pH on cytotoxicity","volume":"65","author":"Phillips","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2006.06.047_bib15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ijc.20005","article-title":"Immunohistochemical analysis of NQO1 and cytochrome P450 reductase in human superficial bladder tumours","volume":"109","author":"Basu","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.juro.2006.06.047_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ijc.10904","article-title":"Glut-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix","volume":"104","author":"Airley","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.juro.2006.06.047_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0006-2952(99)00405-0","article-title":"The relative importance of NADPH:cytochrome C (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions","volume":"59","author":"Saunders","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.juro.2006.06.047_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1023\/A:1015974126615","article-title":"Nitroxides as antioxidants","volume":"234\u2013235","author":"Samuni","year":"2002","journal-title":"Mol Cell Biochem"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706014261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706014261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2006.06.047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:43:16Z","timestamp":1651196596000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2006.06.047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1016\/j.juro.2006.06.047"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2006.06.047","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}